Base de dados : MEDLINE
Pesquisa : C10.597.606.115 [Categoria DeCS]
Referências encontradas : 1913 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 192 ir para página                         

  1 / 1913 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776205
[Au] Autor:Singh R; Bansal R
[Ad] Endereço:University Institute of Pharmaceutical Sciences, Panjab University , Chandigarh 160 014, India.
[Ti] Título:Investigations on 16-Arylideno Steroids as a New Class of Neuroprotective Agents for the Treatment of Alzheimer's and Parkinson's Diseases.
[So] Source:ACS Chem Neurosci;8(1):186-200, 2017 01 18.
[Is] ISSN:1948-7193
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neuroinflammatory mechanisms mediated by activated glial and cytokines (TNF-α, IL-1ß) might contribute to neuronal degeneration leading to Alzheimer's (AD) and Parkinson's disease (PD). Lipopolysaccharide (LPS) is an inflammogen derived from the cell wall of Gram-negative bacteria, which promotes neuroinflammation and subsequent neurodegeneration. Dehydroepiandrosterone (DHEA) and testosterone have been reported as neuroprotective steroids useful for the treatment of various neurodegenerative disorders. In the present study, several 16-arylidene steroidal derivatives have been evaluated as neuroprotective agents in LPS-treated animal models. It was observed that 16-arylidene steroidal derivatives 1a-d and 6a-h considerably improve LPS-induced learning, memory, and movement deficits in animal models. Biochemical estimations of brain serum of treated animals revealed suppression of oxidative and nitrosative stress, acetylcholinesterase activity, and reduction in TNF-α levels, which were induced through LPS mediated neuroinflammatory mechanisms leading to neurodegeneration of brain. Of all the steroidal derivatives, 16-(4-pyridylidene) steroid 1c and its 4-aza analogue 6c were found to be the most active neuroprotective agents and produced effects comparable to standard drug celecoxib at a much lower dose and better than dexamethasone at the same dose in terms of behavioral, biochemical, and molecular aspects.
[Mh] Termos MeSH primário: Encefalite/tratamento farmacológico
Fármacos Neuroprotetores/química
Fármacos Neuroprotetores/uso terapêutico
Esteroides/uso terapêutico
[Mh] Termos MeSH secundário: Acetilcolinesterase/metabolismo
Análise de Variância
Animais
Catatonia/etiologia
Citocinas/metabolismo
Modelos Animais de Doenças
Encefalite/induzido quimicamente
Encefalite/complicações
Glutationa/metabolismo
Peroxidação de Lipídeos/efeitos dos fármacos
Lipopolissacarídeos/toxicidade
Masculino
Aprendizagem em Labirinto/efeitos dos fármacos
Camundongos
Modelos Moleculares
Simulação de Acoplamento Molecular
Fármacos Neuroprotetores/síntese química
Ratos
Esteroides/síntese química
Esteroides/química
Superóxido Dismutase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cytokines); 0 (Lipopolysaccharides); 0 (Neuroprotective Agents); 0 (Steroids); EC 1.15.1.1 (Superoxide Dismutase); EC 3.1.1.7 (Acetylcholinesterase); GAN16C9B8O (Glutathione)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1021/acschemneuro.6b00313


  2 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29182842
[Au] Autor:Nakajima S; Aoshima T; Kuranobu T; Motohashi I; Katayama J; Ueda T; Kamiya T
[Ti] Título:[Case Report ; Malignant catatonia in a patient with schizophrenia.]
[So] Source:Nihon Naika Gakkai Zasshi;105(5):887-892, 2016 May.
[Is] ISSN:0021-5384
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Catatonia/complicações
Esquizofrenia/complicações
[Mh] Termos MeSH secundário: Catatonia/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Esquizofrenia/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  3 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28841632
[Au] Autor:Wilson JE; Carlson R; Duggan MC; Pandharipande P; Girard TD; Wang L; Thompson JL; Chandrasekhar R; Francis A; Nicolson SE; Dittus RS; Heckers S; Ely EW; Delirium and Catatonia (DeCat) Prospective Cohort Investigation
[Ad] Endereço:1Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN. 2Veteran's Affairs Tennessee Valley Healthcare System, Geriatrics, Research, Education and Clinical Center (GRECC), Nashville, TN. 3Division of General Internal Medicine and Public Health, Department of Medicine, Center for Health Services Research, Vanderbilt University Medical Center, Nashville, TN. 4Division of Anesthesiology Critical Care Medicine, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN. 5Department of Critical Care Medicine, Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh School of Medicine, Pittsburgh, PA. 6Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN. 7Department of Psychiatry, Penn State Medical School, Hershey Medical Center, Hershey, PA. 8Department of Psychiatry, Beth Israel Deaconess Hospital-Plymouth, Plymouth, MA. 9Division of Pulmonary and Critical Care, Department of Medicine, and the Institute for Medicine and Public Health, the Center for Health Services Research, Vanderbilt University Medical Center, Nashville, TN.
[Ti] Título:Delirium and Catatonia in Critically Ill Patients: The Delirium and Catatonia Prospective Cohort Investigation.
[So] Source:Crit Care Med;45(11):1837-1844, 2017 Nov.
[Is] ISSN:1530-0293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Catatonia, a condition characterized by motor, behavioral, and emotional changes, can occur during critical illness and appear as clinically similar to delirium, yet its management differs from delirium. Traditional criteria for medical catatonia preclude its diagnosis in delirium. Our objective in this investigation was to understand the overlap and relationship between delirium and catatonia in ICU patients and determine diagnostic thresholds for catatonia. DESIGN: Convenience cohort, nested within two ongoing randomized trials. SETTING: Single academic medical center in Nashville, TN. PATIENTS: We enrolled 136 critically ill patients on mechanical ventilation and/or vasopressors, randomized to two usual care sedation regimens. MEASUREMENTS AND MAIN RESULTS: Patients were assessed for delirium and catatonia by independent and masked personnel using Confusion Assessment Method for the ICU and the Bush Francis Catatonia Rating Scale mapped to Diagnostic Statistical Manual 5 criterion A for catatonia. Of 136 patients, 58 patients (43%) had only delirium, four (3%) had only catatonia, 42 (31%) had both, and 32 (24%) had neither. In a logistic regression model, more catatonia signs were associated with greater odds of having delirium. For example, patient assessments with greater than or equal to three Diagnostic Statistical Manual 5 symptoms (75th percentile) had, on average, 27.8 times the odds (interquartile range, 12.7-60.6) of having delirium compared with patient assessments with zero Diagnostic Statistical Manual 5 criteria (25th percentile) present (p < 0.001). A cut-off of greater than or equal to 4 Bush Francis Catatonia Screening Instrument items was both sensitive (91%; 95% CI, 82.9-95.3) and specific (91%; 95% CI, 87.6-92.9) for Diagnostic Statistical Manual 5 catatonia. CONCLUSIONS: Given that about one in three patients had both catatonia and delirium, these data prompt reconsideration of Diagnostic Statistical Manual 5 criteria for "Catatonic Disorder Due to Another Medical Condition" that preclude diagnosing catatonia in the presence of delirium.
[Mh] Termos MeSH primário: Catatonia/diagnóstico
Catatonia/epidemiologia
Estado Terminal
Delírio/diagnóstico por imagem
Delírio/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Unidades de Terapia Intensiva/estatística & dados numéricos
Masculino
Meia-Idade
Estudos Prospectivos
Reprodutibilidade dos Testes
Respiração Artificial/métodos
Índice de Gravidade de Doença
Vasoconstritores/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Vasoconstrictor Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171111
[Lr] Data última revisão:
171111
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170826
[St] Status:MEDLINE
[do] DOI:10.1097/CCM.0000000000002642


  4 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28655774
[Au] Autor:Vernon RM; Chong PA; Lin H; Yang Z; Zhou Q; Aleksandrov AA; Dawson JE; Riordan JR; Brouillette CG; Thibodeau PH; Forman-Kay JD
[Ad] Endereço:From the Program in Molecular Medicine, Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.
[Ti] Título:Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations.
[So] Source:J Biol Chem;292(34):14147-14164, 2017 Aug 25.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Characterization of the second nucleotide-binding domain (NBD2) of the cystic fibrosis transmembrane conductance regulator (CFTR) has lagged behind research into the NBD1 domain, in part because NBD1 contains the F508del mutation, which is the dominant cause of cystic fibrosis. Research on NBD2 has also been hampered by the overall instability of the domain and the difficulty of producing reagents. Nonetheless, multiple disease-causing mutations reside in NBD2, and the domain is critical for CFTR function, because channel gating involves NBD1/NBD2 dimerization, and NBD2 contains the catalytically active ATPase site in CFTR. Recognizing the paucity of structural and biophysical data on NBD2, here we have defined a bioinformatics-based method for manually identifying stabilizing substitutions in NBD2, and we used an iterative process of screening single substitutions against thermal melting points to both produce minimally mutated stable constructs and individually characterize mutations. We present a range of stable constructs with minimal mutations to help inform further research on NBD2. We have used this stabilized background to study the effects of NBD2 mutations identified in cystic fibrosis (CF) patients, demonstrating that mutants such as N1303K and G1349D are characterized by lower stability, as shown previously for some NBD1 mutations, suggesting a potential role for NBD2 instability in the pathology of CF.
[Mh] Termos MeSH primário: Regulador de Condutância Transmembrana em Fibrose Cística/genética
Fibrose Cística/genética
Mutação Puntual
[Mh] Termos MeSH secundário: Adenosina Trifosfatases/química
Adenosina Trifosfatases/genética
Adenosina Trifosfatases/metabolismo
Trifosfato de Adenosina/química
Trifosfato de Adenosina/metabolismo
Substituição de Aminoácidos
Sítios de Ligação
Domínio Catalítico
Catatonia
Biologia Computacional
Fibrose Cística/metabolismo
Regulador de Condutância Transmembrana em Fibrose Cística/química
Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo
Estabilidade Enzimática
Deleção de Genes
Células HEK293
Seres Humanos
Fusão de Membrana
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Domínios e Motivos de Interação entre Proteínas
Estabilidade Proteica
Proteínas Recombinantes/química
Proteínas Recombinantes/metabolismo
Temperatura de Transição
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CFTR protein, human); 0 (Peptide Fragments); 0 (Recombinant Proteins); 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator); 8L70Q75FXE (Adenosine Triphosphate); EC 3.6.1.- (Adenosine Triphosphatases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M116.772335


  5 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28422845
[Au] Autor:Ohi K; Kuwata A; Shimada T; Yasuyama T; Nitta Y; Uehara T; Kawasaki Y
[Ad] Endereço:aDepartment of Neuropsychiatry bClinical Training Center, Kanazawa Medical University, Ishikawa, Japan.
[Ti] Título:Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report.
[So] Source:Medicine (Baltimore);96(16):e6566, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Malignant catatonia (MC) is a disorder consisting of catatonic symptoms, hyperthermia, autonomic instability, and altered mental status. Neuroleptic malignant syndrome (NMS) caused by antipsychotics is considered a variant of MC. Benzodiazepine (BZD) medications are safe and effective treatments providing rapid relief from MC. This case study reports a detailed clinical course of a case of MC associated with schizophrenia initially diagnosed as NMS that responded successfully to BZDs but not to dantrolene. CASE PRESENTATION: A 53-year-old man with schizophrenia was admitted to the psychiatric hospital because of excitement, monologue, muscle rigidity, and insomnia. In the 3 days before admission, the patient had discontinued his medications after his family member's death. He presented with hyperthermia, tachycardia, hypertension, excessive sweating, and an elevated serum creatine phosphokinase (CPK) level. On the basis of these features, he was suspected to have NMS. The patient was treated with dantrolene for 7 days without improvement despite having a normalized serum CPK level. The patient was transferred to our university hospital for an in-depth examination and treatment of his physical status. Infection and pulmonary embolism were excluded as possible causes. To treat his excitement and auditory hallucination, an intravenous drip (IVD) of haloperidol was initiated, but this treatment increased the patient's catatonic and psychotic symptoms, although his serum CPK level had remained within a normal range. As a result, the treatment was changed to diazepam. After an IVD of diazepam, the patient's symptoms rapidly improved, and the IVD was subsequently replaced with oral administration of lorazepam. Eventually, the patient was diagnosed with MC associated with schizophrenia. BZD therapy was dramatically effective. CONCLUSION: Catatonia, MNS, and MC may be due to a common brain pathophysiology and these conditions may be in a spectrum, although uncertainty in the boundaries among conditions, and the BZD treatment may be useful. Most importantly, catatonia has not been described as a subtype of schizophrenia on the basis of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, and the medications for catatonia and schizophrenia are different. Antipsychotics are not effective in relieving catatonia, or they may induce NMS, whereas BZDs are effective for treating both MC and NMS.
[Mh] Termos MeSH primário: Benzodiazepinas/uso terapêutico
Catatonia/tratamento farmacológico
Catatonia/etiologia
Esquizofrenia/complicações
[Mh] Termos MeSH secundário: Antipsicóticos/efeitos adversos
Creatina Quinase/sangue
Seres Humanos
Masculino
Meia-Idade
Síndrome Maligna Neuroléptica/tratamento farmacológico
Esquizofrenia/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 12794-10-4 (Benzodiazepines); EC 2.7.3.2 (Creatine Kinase)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006566


  6 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
[PMID]:28393979
[Au] Autor:Gaete G; Velásquez Á
[Ad] Endereço:Unidad de Neurofisiología, Hospital de Carabineros de Chile, Santiago, Chile.
[Ti] Título:[Ictal catatonia presentation as a non-convulsive status epilepticus: A case report].
[Ti] Título:Catatonia ictal en el Servicio de Urgencia: una rara forma de presentación del estado epiléptico no convulsivo..
[So] Source:Rev Med Chil;145(1):126-130, 2017 Jan.
[Is] ISSN:0717-6163
[Cp] País de publicação:Chile
[La] Idioma:spa
[Ab] Resumo:The differential diagnosis of non-convulsive status epilepticus (NCSE) is often complex due to a wide clinical variability of its presentation, including psychiatric manifestations. We report a 68 years old male with a history of depression treated with venlafaxine, mirtazapine, quetiapine and risperidone, presenting in the emergency room with confusion and generalized rigidity. A brain CT scan did not show lesions. A neuroleptic syndrome was initially suspected. At the third day the obtundation worsened and an electroencephalogram (EEG) was performed, which showed epileptiform abnormalities. Treatment with valproic acid resulted in disappearance of such abnormalities. After three weeks of mechanical ventilation, the patient was extubated and remained lucid and partially orientated in time and space.
[Mh] Termos MeSH primário: Catatonia/etiologia
Estado Epiléptico/complicações
[Mh] Termos MeSH secundário: Idoso
Eletroencefalografia
Seres Humanos
Masculino
Estado Epiléptico/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE


  7 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28352494
[Au] Autor:Wong JW; Williams SR
[Ti] Título:The Wandering Woman: A Case Study of Catatonia vs Factitious Disorder.
[So] Source:Hawaii J Med Public Health;76(3):82-84, 2017 Mar.
[Is] ISSN:2165-8242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 61-year-old woman with an unknown psychiatric history presented with mutism, stupor, negativism, and withdrawn behavior. She was admitted to the psychiatric unit for what appeared to be catatonia. Medical records were not readily available. A comprehensive evaluation did not uncover any medical etiology. Lorazepam was ineffective at consistently reversing her catatonic symptoms. During week three of hospitalization, she was given olanzapine with subsequent improvement in her negativism. Several physicians believed her catatonic symptoms were feigned given multiple episodes of spontaneous purposeful movement when she was not under the direct supervision of staff. There is minimal literature on distinguishing catatonia and factitious disorder. This distinction is crucial because these diagnoses require very different treatments, and the iatrogenic complications related to the treatment of catatonia with high-dose benzodiazepines and electroconvulsive therapy are significant. Rapid access to electronic health records can facilitate treatment for patients who cannot provide a medical history, especially when factitious disorder is included in the differential diagnosis.
[Mh] Termos MeSH primário: Catatonia/diagnóstico
Transtornos Autoinduzidos/diagnóstico
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Feminino
Seres Humanos
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE


  8 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28202296
[Au] Autor:Fisher J; Ellingson C; Tolby N
[Ad] Endereço:University of Arizona, College of Medicine, Tucson, AZ, USA. Electronic address: Jhfisher@email.arizona.edu.
[Ti] Título:Psychosis in the ED: A case of NMDA receptor antibody encephalitis.
[So] Source:Am J Emerg Med;35(7):1035.e5-1035.e6, 2017 Jul.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anti-N-methyl-d-aspartate antibody receptor (NMDAR) encephalitis is a newly recognized disease increasing in diagnostic frequency. A 27-year-old female presented with symptoms of oral dyskinesia, tachycardia, and altered mental status following a three-month history of depression, lethargy, catatonia, and auditory hallucinations. We utilized our facilities neurology and psychiatry consult services, performed a lumbar puncture (LP), and requested NMDAR antibody titers. Following admission the Anti-NMDAR antibody titer was elevated warranting treatment with intravenous immunoglobulin (IVIG), corticosteroids, and later rituximab. Organic causes of psychosis are often overlooked in the emergency department, particularly in patients with a history of psychiatric illness. An understanding and awareness of NMDAR encephalitis allows for timely diagnosis, prompting quicker treatment. Emergency physicians should maintain an index of clinical suspicion for NMDAR encephalitis when encountering patients with progressive symptoms of catatonia and psychosis of unclear etiology.
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Encefalite Antirreceptor de N-Metil-D-Aspartato/diagnóstico
Transtorno Bipolar/complicações
Serviço Hospitalar de Emergência
Imunoglobulinas Intravenosas/uso terapêutico
Transtornos Psicóticos/diagnóstico
Rituximab/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Encefalite Antirreceptor de N-Metil-D-Aspartato/imunologia
Encefalite Antirreceptor de N-Metil-D-Aspartato/fisiopatologia
Encefalite Antirreceptor de N-Metil-D-Aspartato/terapia
Anticorpos
Transtorno Bipolar/fisiopatologia
Catatonia
Diagnóstico Diferencial
Feminino
Hidratação/métodos
Alucinações
Seres Humanos
Transtornos Psicóticos/etiologia
Transtornos Psicóticos/imunologia
Receptores de N-Metil-D-Aspartato/análise
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Antibodies); 0 (Immunoglobulins, Intravenous); 0 (Receptors, N-Methyl-D-Aspartate); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170217
[St] Status:MEDLINE


  9 / 1913 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28114315
[Au] Autor:Lin CC; Hung YY; Tsai MC; Huang TL
[Ad] Endereço:Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
[Ti] Título:The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry.
[So] Source:PLoS One;12(1):e0170452, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The lorazepam-diazepam protocol had been proved to rapidly and effectively relieve catatonia in patients with schizophrenia or mood disorder. This study aims to investigate the efficacy of lorazepam-diazepam protocol in catatonia due to general medical conditions (GMC) and substance. METHOD: Patients with catatonia that required psychiatric intervention in various settings of a medical center were included. The lorazepam-diazepam protocol had been used to treat the catatonia due to GMC or substance according to DSM-IV criteria. The treatment response had been assessed by two psychiatrists. RESULTS: Eighteen (85.7%) of 21 catatonic patients due to GMC or substance became free of catatonia after the lorazepam-diazepam protocol. Five (23.8%) of the 21 patients had passed away with various causes of death and wide range of time periods after catatonia. CONCLUSION: Our results showed that the lorazepam-diazepam protocol could rapidly and effectively relieve catatonia due to GMC and substance.
[Mh] Termos MeSH primário: Catatonia/tratamento farmacológico
Diazepam/administração & dosagem
Lorazepam/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Manual Diagnóstico e Estatístico de Transtornos Mentais
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
O26FZP769L (Lorazepam); Q3JTX2Q7TU (Diazepam)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170124
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0170452


  10 / 1913 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28099562
[Au] Autor:Nunes AL; Filgueiras A; Nicolato R; Alvarenga JM; Silveira LA; Silva RA; Cheniaux E
[Ad] Endereço:Universidade Federal do Rio de Janeiro, Instituto de Psiquiatria, Rio de Janeiro RJ, Brasil.
[Ti] Título:Development and validation of the Bush-Francis Catatonia Rating Scale - Brazilian version.
[So] Source:Arq Neuropsiquiatr;75(1):44-49, 2017 Jan.
[Is] ISSN:1678-4227
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objective:: This article aims to describe the adaptation and translation process of the Bush-Francis Catatonia Rating Scale (BFCRS) and its reduced version, the Bush-Francis Catatonia Screening Instrument (BFCSI) for Brazilian Portuguese, as well as its validation. Methods:: Semantic equivalence processes included four steps: translation, back translation, evaluation of semantic equivalence and a pilot-study. Validation consisted of simultaneous applications of the instrument in Portuguese by two examiners in 30 catatonic and 30 non-catatonic patients. Results:: Total scores averaged 20.07 for the complete scale and 7.80 for its reduced version among catatonic patients, compared with 0.47 and 0.20 among non-catatonic patients, respectively. Overall values of inter-rater reliability of the instruments were 0.97 for the BFCSI and 0.96 for the BFCRS. Conclusion:: The scale's version in Portuguese proved to be valid and was able to distinguish between catatonic and non-catatonic patients. It was also reliable, with inter-evaluator reliability indexes as high as those of the original instrument.
[Mh] Termos MeSH primário: Catatonia/diagnóstico
Manual Diagnóstico e Estatístico de Transtornos Mentais
Inquéritos e Questionários
[Mh] Termos MeSH secundário: Brasil
Estudos de Casos e Controles
Características Culturais
Seres Humanos
Psicometria
Fatores Socioeconômicos
Traduções
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE



página 1 de 192 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde